These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38642729)

  • 1. Challenges and gaps in immunosafety evaluation of therapeutics: An IQ DruSafe survey.
    Collinge M; Neff-LaFord H; Akella S; Fogal B; Fraser K; Jabbour J; Harper K; Maier CC; Malherbe L; Marshall N; Rao GK; Raman K; Skaggs H; Weber F; Fuller CL
    Regul Toxicol Pharmacol; 2024 Jun; 150():105630. PubMed ID: 38642729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.
    Piccotti JR; Lebrec HN; Evans E; Herzyk DJ; Hastings KL; Burns-Naas LA; Gourley IS; Wierda D; Kawabata TT
    J Immunotoxicol; 2009 Mar; 6(1):1-10. PubMed ID: 19519157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
    Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
    Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical industry perspective on combination toxicity studies: Results from an intra-industry survey conducted by IQ DruSafe Leadership Group.
    Birkebak J; Buckley LA; Dambach D; Musvasva E; Price K; Ralston S; Sacaan A
    Regul Toxicol Pharmacol; 2019 Mar; 102():40-46. PubMed ID: 30576687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune function tests for hazard identification: a paradigm shift in drug development.
    Gore ER
    Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):331-5. PubMed ID: 16623854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
    Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
    Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
    Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
    J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug development and nonclinical to clinical translational databases: past and current efforts.
    Monticello TM
    Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine release assays: current practices and future directions.
    Finco D; Grimaldi C; Fort M; Walker M; Kiessling A; Wolf B; Salcedo T; Faggioni R; Schneider A; Ibraghimov A; Scesney S; Serna D; Prell R; Stebbings R; Narayanan PK
    Cytokine; 2014 Apr; 66(2):143-55. PubMed ID: 24412476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry: Results of an IQ DruSafe Minipig Survey.
    Colleton C; Brewster D; Chester A; Clarke DO; Heining P; Olaharski A; Graziano M
    Toxicol Pathol; 2016 Apr; 44(3):458-66. PubMed ID: 27006130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies.
    MacLachlan TK; Kronenberg S; Marshall N; Andrews L; Berens SJ; Brouta F; Fogal B; Freebern W; Herzyk D; Kamperschroer C; Kiessling A; Schneidkraut M; Maier C
    Regul Toxicol Pharmacol; 2021 Feb; 119():104825. PubMed ID: 33220389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary.
    Baker TK; Van Vleet TR; Mahalingaiah PK; Grandhi TSP; Evers R; Ekert J; Gosset JR; Chacko SA; Kopec AK
    Drug Metab Dispos; 2024 Feb; 52(3):198-209. PubMed ID: 38123948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure assessments in reproductive and developmental toxicity testing: An IQ-DruSafe industry survey on current practices and experiences in support of exposure-based high dose selection.
    Andrews PA; McNerney ME; DeGeorge JJ
    Regul Toxicol Pharmacol; 2019 Oct; 107():104413. PubMed ID: 31229519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory forum opinion piece*: immunotoxicology assessments in nonhuman primates--challenges and opportunities.
    Lebrec HN
    Toxicol Pathol; 2013; 41(3):548-51. PubMed ID: 22886347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices.
    Bogdanffy MS; Lesniak J; Mangipudy R; Sistare FD; Colman K; Garcia-Tapia D; Monticello T; Blanset D
    Int J Toxicol; 2020; 39(3):198-206. PubMed ID: 32372678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative.
    DaSilva JK; Breidenbach L; Deats T; Li D; Treinen K; Dinklo T; Kervyn S; Teuns G; Traebert M; Hempel K
    J Pharmacol Toxicol Methods; 2020; 103():106683. PubMed ID: 32105757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Trends of Practices in Nonclinical Toxicology: An Industry Survey.
    Authier S; Brock WJ; Halpern W; Harris SN; Jones D; McGovern T; McGovern PD; Pugsley MK
    Int J Toxicol; 2021 Dec; 40(6):487-505. PubMed ID: 34569357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.